Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?

2 Feb 2018

Abstract excerpt

PARP inhibitors can induce synthetic lethality in tumors characterized by homologous recombination deficiency (HRD), which can be detected by evaluating genome-wide loss of heterozygosity (LOH). Multiple myeloma (MM) is a genetically unstable tumor and we hypothesized that HRD-related LOH (HRD-LOH) could be detected in patient samples, supporting a potential role for PARP inhibition in MM. Using results from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy
Share to Plant Genetic and Mutation Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29467487
DOI: 10.1038/s41375-018-0017-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?PMID 29467487Read ↗

DNA damage repair (DDR) related prognostic risk model in multiple myeloma based on single-cell and bulk sequencing.Semantic proximity Read ↗

Dysfunctional homologous recombination mediates genomic instability and progression in myeloma.Semantic proximity Read ↗

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myelomaSemantic proximity Read ↗

From Germline Susceptibility to Therapeutic Vulnerability: DNA Damage Response Gene Mutations Driving Multiple Myeloma Evolution and Precision Therapy.Semantic proximity Read ↗

Determining PARP Inhibition as a Treatment Strategy in Melanoma Based on Homologous Recombination Deficiency–Related Loss of HeterozygositySemantic proximity Read ↗

DNA repair pathways in human multiple myelomaSemantic proximity Read ↗

Treatment May Be Harmful: Mechanisms/Prediction/Prevention of Drug-Induced DNA Damage and Repair in Multiple MyelomaSemantic proximity Read ↗

Understanding DNA Damage Response and DNA Repair in Multiple MyelomaSemantic proximity Read ↗

Recent Advances in Genomic Approaches for the Detection of Homologous Recombination Deficiency.Semantic proximity Read ↗

Exploiting MYC-induced PARPness to target genomic instability in multiple myelomaSemantic proximity Read ↗

Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibitionSemantic proximity Read ↗

Establishing the homologous recombination score threshold in metastatic prostate cancer patients to predict the efficacy of PARP inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.